Additionally, both trials met key secondary endpoints measuring PsA disease activity at week 16. The safety profile of deucravacitinib ... that oral Sotyktu has the potential to be the first TYK2 ...
Psoriatic arthritis (PsA) most often attacks and damages ... Psoriasis and PsA are inflammatory diseases, increasing your risk for periodontitis and tooth decay. The more severe your PsA symptoms ...
Introduction: The relationship between the phenotype and treatment of psoriatic arthritis (PsA) and the increased prevalence of cardiovascular comorbidities is not well studied. Objective: To assess ...